SCHEMBL4482181

SCHEMBL4482181

Cc1sc2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cccc(F)c2)c(F)c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.81
TEK Q02763 16/20 0.81
KIT P10721 16/20 0.81
FLT3 P36888 3/20 0.62
LCK P06239 2/20 0.61
CSF1R P07333 2/20 0.61
FGFR1 P11362 2/20 0.61
FLT1 P17948 2/20 0.61
FGFR3 P22607 2/20 0.61
FLT4 P35916 2/20 0.61
PDGFRB P09619 1/20 0.61
PDGFRA P16234 1/20 0.61
FGFR2 P21802 1/20 0.61
FGFR4 P22455 1/20 0.61
AURKA O14965 2/20 0.60
PLK4 O00444 1/20 0.59
PDPK1 O15530 1/20 0.59
DAPK3 O43293 1/20 0.59
DYRK3 O43781 1/20 0.59
ROCK2 O75116 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4488155 0.93 KDR (0.78) KDRTEKKITFLT3LCK
SCHEMBL4469139 0.92 KDR (0.79) KDRTEKKITFLT3LCK
SCHEMBL4488194 0.91 KDR (0.79) KDRTEKKITFLT3LCK
SCHEMBL4480179 0.91 KDR (0.79) KDRTEKKITFLT3LCK
SCHEMBL4470204 0.90 KDR (1.00) KDRTEKKITFLT3LCK
SCHEMBL4476167 0.90 KDR (0.81) KDRTEKKITFLT3LCK
SCHEMBL4471698 0.90 KDR (0.66) KDRTEKKITFLT3LCK
SCHEMBL4473359 0.88 KDR (0.71) KDRTEKKITFLT3LCK
SCHEMBL4468584 0.88 KDR (0.81) KDRTEKKITFLT3LCK
SCHEMBL4474498 0.88 KDR (0.77) KDRTEKKITFLT3LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560552-B2 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES (US) 2009-07-14 US disclosed
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors MICHAELIDES MICHAEL R 2006-12-07 US disclosed
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBVIE INC. 2004-01-22 US disclosed
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885TEK 328/4885KIT 394/4885
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors ABL1, LCK, ERBB2 KDR 391/4885TEK 324/4885KIT 361/4885
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885TEK 328/4885KIT 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.